Inflammation-related markers in COVID-19 infection and ST-segment elevation myocardial infarction.

IF 1.4 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Minerva cardiology and angiology Pub Date : 2024-11-29 DOI:10.23736/S2724-5683.24.06639-0

Nart Z Baytuğan, Hasan C Kandemir, Aziz I Çelik, Tahir Bezgin

{"title":"Inflammation-related markers in COVID-19 infection and ST-segment elevation myocardial infarction.","authors":"Nart Z Baytuğan, Hasan C Kandemir, Aziz I Çelik, Tahir Bezgin","doi":"10.23736/S2724-5683.24.06639-0","DOIUrl":null,"url":null,"abstract":"Background: The aim of this study is to investigate the association between inflammation-related markers in COVID-19 infection and ST-segment elevation myocardial infarction (STEMI).Methods: We conducted an observational, single-center, retrospective study between January 2020 and November 2022. A total of 149 patients aged between 34 and 90 years, 28.2% (N.=42) female and 71.8% (N.=107) male, were included in the study. Systemic immune-inflammation index (SII), systemic inflammation-response indexes (SIRI), platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) were calculated for each patient. The patients were divided into two groups based on their presence or absence of a confirmed SARS-CoV-2 infection.Results: During the in-hospital follow-up, mortality occurred in 12% (N.=20) of patients. Among the COVID-19 (+) and STEMI group, the mortality rate was 24.3% (N.=10), while it was 5.6% (N.=6) in the COVID-19 (-) and STEMI group (P=0.001). In multivariate logistic regression analysis, SII ([HR] = 7.198 [1.423-36.411], P=0.017) and PLR ([HR] = 5.762 [1.783-18.619], P=0.003) remained significant risk factor for mortality.Conclusions: The SII, SIRI, NLR, and PLR are relatively new, simple, and effective inflammation-related markers that determine mortality risk in STEMI patients.","PeriodicalId":18668,"journal":{"name":"Minerva cardiology and angiology","volume":" ","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva cardiology and angiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.23736/S2724-5683.24.06639-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The aim of this study is to investigate the association between inflammation-related markers in COVID-19 infection and ST-segment elevation myocardial infarction (STEMI).

Methods: We conducted an observational, single-center, retrospective study between January 2020 and November 2022. A total of 149 patients aged between 34 and 90 years, 28.2% (N.=42) female and 71.8% (N.=107) male, were included in the study. Systemic immune-inflammation index (SII), systemic inflammation-response indexes (SIRI), platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) were calculated for each patient. The patients were divided into two groups based on their presence or absence of a confirmed SARS-CoV-2 infection.

Results: During the in-hospital follow-up, mortality occurred in 12% (N.=20) of patients. Among the COVID-19 (+) and STEMI group, the mortality rate was 24.3% (N.=10), while it was 5.6% (N.=6) in the COVID-19 (-) and STEMI group (P=0.001). In multivariate logistic regression analysis, SII ([HR] = 7.198 [1.423-36.411], P=0.017) and PLR ([HR] = 5.762 [1.783-18.619], P=0.003) remained significant risk factor for mortality.

Conclusions: The SII, SIRI, NLR, and PLR are relatively new, simple, and effective inflammation-related markers that determine mortality risk in STEMI patients.

查看原文本刊更多论文

COVID-19感染与st段抬高型心肌梗死的炎症相关标志物

背景：本研究旨在探讨COVID-19感染中炎症相关标志物与st段抬高型心肌梗死（STEMI）的相关性。方法：我们于2020年1月至2022年11月进行了一项观察性、单中心、回顾性研究。共纳入34 ~ 90岁患者149例，其中女性42例（28.2%），男性107例（71.8%）。计算每位患者的全身免疫炎症指数（SII）、全身炎症反应指数（SIRI）、血小板与淋巴细胞比值（PLR）和中性粒细胞与淋巴细胞比值（NLR）。根据患者是否存在确诊的SARS-CoV-2感染，将患者分为两组。结果：住院随访期间，有12% （n =20）患者死亡。在COVID-19（+）和STEMI组中，死亡率为24.3% (n =10)，而COVID-19（-）和STEMI组死亡率为5.6% (n =6) （P=0.001）。多因素logistic回归分析显示，SII （[HR] = 7.198 [1.423-36.411]， P=0.017）和PLR （[HR] = 5.762 [1.783-18.619]， P=0.003）仍是死亡率的显著危险因素。结论：SII、SIRI、NLR和PLR是相对较新的、简单有效的炎症相关标志物，可确定STEMI患者的死亡风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊